Zacks Investment Research upgraded shares of INC RESRCH HLDG (INCR) from NEUTRAL to OUTPERFORM on February 27, 2015, with a target price of $33.20.
INC Research Holdings, Inc. is a global contract research organization. It provides the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Its services include clinical trial management services comprising patient recruitment and retention, project management, clinical monitoring, drug safety/pharmacovigilance, medical affairs, quality assurance, regulatory and medical writing, and functional service and data services consisting of clinical data management, electronic data capture, and biostatistics. INC Research Holdings, Inc. is headquartered in Raleigh, North Carolina.
To get a free copy of the research report on INC RESRCH HLDG (INCR),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment